Mesar

Olmesartan medoxomil, the active ingredient in Mesar, is an Angiotensin II receptor blocker (ARB) presented as an oral tablet for oral administration. It is indicated for the management of hypertension in adult patients, helping to lower elevated blood pressure and reduce cardiovascular risk.

GNH USA supplies Mesar as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, providing reliable access to quality‑assured antihypertensive medication.

Olmesartan medoxomil is an ARB used to treat conditions related to the renin‑angiotensin system, primarily hypertension. - Hypertension: lowers systolic and diastolic blood pressure in patients with essential hypertension. - High blood pressure: assists in achieving target blood pressure levels as part of antihypertensive therapy. - Cardiovascular risk management: contributes to risk reduction by controlling blood pressure in at‑risk adults.

Common Side Effects: - Dizziness: sensation of light‑headedness, especially after standing. - Headache: mild to moderate pain in the head region. - Fatigue: feeling unusually tired or weak. - Abdominal pain: discomfort or cramping in the stomach area. - Nasal congestion: blocked or runny nose. - Back pain: soreness in the lower back.

Serious or Rare Side Effects: - Angioedema: swelling of the face, lips, tongue, or throat that may impair breathing. - Hyperkalemia: elevated potassium levels that can affect heart rhythm. - Acute renal failure: sudden loss of kidney function. - Severe hypotension: markedly low blood pressure causing faintness. - Liver injury: abnormal liver function tests or hepatitis. - Anaphylactic reaction: severe allergic response requiring immediate medical attention.

Olmesartan medoxomil should be used with caution in specific clinical situations. - Pregnancy: contraindicated in pregnancy (Category D) due to risk of fetal toxicity. - Renal impairment: monitor kidney function and adjust therapy as needed. - Hepatic impairment: use with caution; assess liver enzymes periodically. - Electrolyte imbalance: watch for hyperkalemia, especially when combined with potassium‑sparing agents. - Concomitant aliskiren in diabetes: avoid combined use due to increased risk of renal complications. - Store at ambient temperature: keep below 25°C in the original packaging, protect from moisture and direct sunlight.

Olmesartan medoxomil may interact with several medicines; monitoring is essential. Major Interactions (Avoid): - Aliskiren in diabetic patients: combined use can increase renal risk. - Dual therapy with ACE inhibitors or other ARBs: may cause excessive hypotension and renal dysfunction. - Potassium‑sparing diuretics or supplements: risk of hyperkalemia. Moderate Interactions (Monitor Closely): - NSAIDs: may reduce antihypertensive efficacy and affect renal function. - Lithium: can increase lithium serum concentrations, risking toxicity. - Thiazide diuretics: may enhance hypotensive effect; monitor blood pressure closely.